retatrutide triple agonist gip glp-1 glucagon receptor Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Retatrutide: How the Triple Agonist

HIMS stock logged its second straight session of losses on Wednesday after declining nearly 3% to $29.01

3 Additional studies are needed to assess the benefits and potential risks of using GLP-1 RAs in HS treatment in patients with and without comorbidities to determine whether GLP-1 RAs should be included in a standardized regimen

The vision loss connection demonstrates an even more troubling pattern

Strength training combined with adequate protein intake helps maintain muscle mass

Who must avoid it entirely in the class framing: anyone pregnant or breastfeeding, anyone with the personal/family MTC or MEN 2 history above, and anyone with prior serious hypersensitivity to a GLP-1 agonist

What the Clinical Data Says About Extended Treatment The backbone of everything we know about extended Retatrutide use comes from the Phase 2 SURMOUNT-1 trial, which tracked 338 participants across multiple dose groups for a full 48 weeks